Do Complex Medicines Present a Different Challenge from a Safety Perspective?

Speaker: Dr Richard Knight

Part of the MDC Connects 2021: A Guide to Complex Medicines is a series of webinars exploring the opportunities and challenges presented by this new class of medicines. The complete webinar included talks by Jenny Worthington (Axis Bio) and Juliana Maynard (MDC) and can be found here.

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments, which require a shift towards stratified, complex medicines with more challenging discovery and development needs. Here experts describe how to establish preclinical safety and efficacy data for complex medicines and how this compares with conventional drug discovery.